Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Postoperative opacification of a hydrophilic-hydrophobic acrylic intraocular lens: analysis of cases from 2010 to date

Poster Details

First Author: M.Alvarez SPAIN

Co Author(s):    A. Martinez-Abad   E. Rivera   F. Lugo Quinto   H. Albertos   V. Vargas   N. Subirana Pacheco   L. Bataille   J. Alio

Abstract Details

Purpose:

To study the prevalence and clinical characteristics of postoperative opacification of a hydrophilic-hydrophobic acrylic intraocular lens (IOL) as well as to analyse the clinical consequences

Setting:

Vissum Corporation, Madrid and Alicante, Spain

Methods:

Prospective observational study comprised by patients operated on different model of IOL Lentis Mplus (LS-312 MF30, LS-313 MF30 and LU-313 MF30T models) since 2010 until 2017. In all cases, a complete eye exam was performed evaluating the uncorrected and corrected distance visual acuity (VA) and the uncorrected and corrected near VA during the longest follow-up period. Opacification cases were registered and analyzed, comparing the data in the moment of the opacification diagnosis with the data in the medical discharge.

Results:

A total of 523 IOL Lentis Mplus were included, detecting 28 opacification cases (prevalence: 5.35%). Twenty seven of twenty eight opacification cases were manufactured before 06/2015 agreeing with the moment when the manufacturer (Oculentis GmbH) stop to use phosphate like a cleaning system. Mean time between the surgery and the opacification diagnosis was 53 months (range 13-86 months). The distribution according to the type of opacification was: 13 peripheral plaques, 6 central plaques and 9 diffused opacification. Nine of them affected visual axis, decreasing VA in 5 cases (VA mean decrease: 3.5 lines). Two cases required LIO explanted.

Conclusions:

Opacification of the Lentis Mplus was found mainly in patients operated with IOLs manufactured before June 2015. Only 0.38% of cases required IOL explant by this reason.

Financial Disclosure:

None

Back to Poster listing